Darifenacin

Drug Profile

Darifenacin

Alternative Names: Darifenacin hydrobromide; Emselex; Enablex; UK 88525

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Developer Allergan; Novartis; Pfizer
  • Class Benzofurans; Pyrrolidines; Small molecules; Urologics
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • Discontinued Irritable bowel syndrome; Small cell lung cancer

Most Recent Events

  • 17 Jul 2017 Merus Labs has been acquired and merged into Norgine
  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
  • 20 Aug 2013 Darifenacin sub-licensed to Merz Pharma in Switzerland, Arriani Pharmaceuticals in Greece, Vivax Pharmaceuticals in Slovakia & Eurocept Pharmaceuticals in Belgium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top